Perrigo CO PLC PRGO
We take great care to ensure that the data presented and summarized in this overview for PERRIGO Co plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRGO
View all-
Vanguard Group Inc Valley Forge, PA14.8MShares$391 Million0.01% of portfolio
-
Black Rock Inc. New York, NY13MShares$342 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX7.16MShares$189 Million0.05% of portfolio
-
State Street Corp Boston, MA6.83MShares$180 Million0.01% of portfolio
-
Deprince Race & Zollo Inc Winter Park, FL3.88MShares$102 Million2.25% of portfolio
-
Cooke & Bieler LP3.5MShares$92.4 Million0.94% of portfolio
-
Thompson Siegel & Walmsley LLC3.15MShares$83.1 Million1.3% of portfolio
-
Copeland Capital Management, LLC2.48MShares$65.5 Million1.16% of portfolio
-
Perpetual LTD Sydney, New South Wales, C32.45MShares$64.6 Million0.7% of portfolio
-
Pendal Group LTD2.45MShares$64.5 Million0.68% of portfolio
Latest Institutional Activity in PRGO
Top Purchases
Top Sells
About PRGO
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Insider Transactions at PRGO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 04
2024
|
Triona Schmelter EVP & President CSCA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,034
-23.3%
|
$24,816
$24.93 P/Share
|
Oct 04
2024
|
Triona Schmelter EVP & President CSCA |
BUY
Exercise of conversion of derivative security
|
Direct |
3,611
+44.27%
|
$86,664
$24.93 P/Share
|
Sep 13
2024
|
Katherine C. Doyle Director |
SELL
Open market or private sale
|
Direct |
8,954
-59.84%
|
$241,758
$27.3 P/Share
|
Aug 26
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Open market or private sale
|
Direct |
13,000
-38.74%
|
$377,000
$29.4 P/Share
|
Aug 20
2024
|
Svend Andersen EVP & President CHCI |
SELL
Open market or private sale
|
Indirect |
6,683
-48.84%
|
$180,441
$27.43 P/Share
|
Aug 20
2024
|
Svend Andersen EVP & President CHCI |
SELL
Open market or private sale
|
Direct |
28,300
-14.86%
|
$764,100
$27.66 P/Share
|
Jul 10
2024
|
Patrick Lockwood Taylor CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,254
-15.54%
|
$411,858
$27.16 P/Share
|
Jul 10
2024
|
Patrick Lockwood Taylor CEO |
BUY
Grant, award, or other acquisition
|
Direct |
11,837
+19.24%
|
$319,599
$27.16 P/Share
|
Jul 10
2024
|
Patrick Lockwood Taylor CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,326
+36.71%
|
$764,802
$27.16 P/Share
|
Jul 08
2024
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
479
-2.53%
|
$11,975
$25.72 P/Share
|
Jul 08
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
920
+4.63%
|
$23,000
$25.72 P/Share
|
Jun 07
2024
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,104
-6.67%
|
$28,704
$26.94 P/Share
|
Jun 07
2024
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,532
+21.48%
|
$117,832
$26.94 P/Share
|
May 28
2024
|
Svend Andersen EVP & President CHCI |
BUY
Open market or private purchase
|
Direct |
1,000
+0.97%
|
$27,000
$27.9 P/Share
|
May 15
2024
|
Erica L Mann Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-19.42%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Erica L Mann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+28.8%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Jeffrey B Kindler Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-15.46%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Jeffrey B Kindler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+24.36%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Albert Manzone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-36.23%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Albert Manzone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+43.01%
|
$262,920
$30.22 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 167K shares |
---|---|
Open market or private purchase | 44.5K shares |
Grant, award, or other acquisition | 69.1K shares |
Payment of exercise price or tax liability | 86.8K shares |
---|---|
Open market or private sale | 56.9K shares |